Sucampo Pharma (SCMP) Tops Q3 EPS by 2c, Guidance Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Sucampo Reports Third Quarter 2016 Financial Results
November 9, 2016 6:30 AM ESTResults Driven by 73% Growth in Revenue
GAAP EPS Growth of 12%; Adjusted EPS Growth of 58%
Company Raises 2016 Guidance and Provides Preliminary 2017 Guidance
Announces Settlement with Dr. Reddys Laboratories for AMITIZA
Reports Phase Three Results for AMITIZA in Pediatric Population
Company to Host Conference Call Today at 8:30 a.m. EST
ROCKVILLE, Md., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals,... More
